Special Issue

Clinical and Therapeutic Implications of Metabolomics in Cancer Immunology

Message from the Guest Editor

This Special Issue will feature reviews and original research articles on innovative methods for the metabolic profiling of immune response, with applications in immune-related pathological conditions. Of particular significance is a study on metabolomic profiles with implications for clinical oncology, employing diverse analysis platforms. Additionally, we will highlight how metabolic changes across cells within the tumor microenvironment can impact immune cell function, potentially influencing the outcomes of immune responses. Therapy resistance remains a critical concern in the field of cancer biology. Consequently, research that employs metabolomics to discover novel target molecules or potential drug targets will be given significant consideration.


Guest Editor

Dr. Jvoti Kaushal

Radiation Oncology, College of Medicine, Fred & Pamela Buffet Cancer Center, University of Nebraska Medical Center, Omaha, NE 68198, USA

Deadline for manuscript submissions

closed (20 April 2024)



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/186501

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

